Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vir Biotechnology Inc V.VIR


Primary Symbol: VIR

Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.


NDAQ:VIR - Post by User

Comment by STOCKINSIDERSon Mar 20, 2019 11:04pm
128 Views
Post# 29514855

RE:RE:this one could get explosive!

RE:RE:this one could get explosive!
cmj1966 wrote:   What do you mean by explosive?? If you look at page 4 of the annual report you are looking at 2.5 million$$$ between G and A,prof fees,salaries and wages and marketing.  Only 771K in Rev on a loss of 4.8 million for the year.  They better tighten up the ship and increase revenue substainlly or they will blow through that 10 million in about 3 years and then throw in the X factor of almost doubling the shares through takeover that were not part of last financials.

  I sold in the seventies for a bit of a loss but will wait for next quarterly to come out and then see how the numbers line up. Co is legit but that,s a big burn rate and any plan for the greenhouses??  That will chew through a few million before they even get a crop!



very very dumb comments imo, a start up like this doing revs already of course it will show losses for a bit, has any pot stock turned a profit? use your head jeusus fuk

<< Previous
Bullboard Posts
Next >>